Video Reports – Melanoma Research Victoria https://melanomaresearchvic.com.au Thu, 24 Sep 2020 07:51:29 +0000 en-US hourly 1 https://melanomaresearchvic.com.au/wp-content/uploads/2017/12/cropped-favicon-32x32.png Video Reports – Melanoma Research Victoria https://melanomaresearchvic.com.au 32 32 Dr. Long on the Rationale for the Phase 3 COMBI-i Trial in BRAF V600¬–Mutant Melanoma https://melanomaresearchvic.com.au/dr-long-on-the-rationale-for-the-phase-3-combi-i-trial-in-braf-v600%c2%ac-mutant-melanoma Thu, 24 Sep 2020 07:51:14 +0000 https://melanomaresearchvic.com.au/?p=15663 Georgina Long, BSc, PhD, MBBS, FRACP, co-medical director, Melanoma Institute Australia (MIA), chair of Melanoma Medical Oncology and Translational Research, MIA and Royal North Shore Hospital, University of Sydney, discusses the rationale for the phase 3 COMBI-i trial in BRAF V600­–mutant melanoma.

The post Dr. Long on the Rationale for the Phase 3 COMBI-i Trial in BRAF V600¬–Mutant Melanoma appeared first on Melanoma Research Victoria.

]]>
Source: OncLive, August 2020

 

Georgina Long, BSc, PhD, MBBS, FRACP, co-medical director, Melanoma Institute Australia (MIA), chair of Melanoma Medical Oncology and Translational Research, MIA and Royal North Shore Hospital, University of Sydney, discusses the rationale for the phase 3 COMBI-i trial in BRAF V600­–mutant melanoma.

The COMBI-i study evaluated the combination of spartalizumab, dabrafenib (Tafinlar), and trametinib (Mekinist), says Long.

Findings from parts 1 and 2 of the phase 3 trial were presented during the 2020 ASCO Virtual Scientific Program and showed encouraging clinical activity and tolerability with the novel triplet.

READ THE ORIGINAL FULL ARTICLE

The post Dr. Long on the Rationale for the Phase 3 COMBI-i Trial in BRAF V600¬–Mutant Melanoma appeared first on Melanoma Research Victoria.

]]>
Dr. Blank on the OpACIN, OpACIN-neo Trials in Stage III Macroscopic Melanoma https://melanomaresearchvic.com.au/dr-blank-on-the-opacin-opacin-neo-trials-in-stage-iii-macroscopic-melanoma Fri, 18 Sep 2020 08:21:01 +0000 https://melanomaresearchvic.com.au/?p=15628 Christian U. Blank, MD, PhD, a medical oncologist in the Division of Immunology at the Netherlands Cancer Institute, discusses the OpACIN and OPACIN-neo trials examining ipilimumab (Yervoy) plus nivolumab (Opdivo) in stage III macroscopic melanoma.

The post Dr. Blank on the OpACIN, OpACIN-neo Trials in Stage III Macroscopic Melanoma appeared first on Melanoma Research Victoria.

]]>
Source: OncLive, September 2020

Christian U. Blank, MD, PhD, a medical oncologist in the Division of Immunology at the Netherlands Cancer Institute, discusses the OpACIN and OPACIN-neo trials examining ipilimumab (Yervoy) plus nivolumab (Opdivo) in stage III macroscopic melanoma.

In the phase 1b OpACIN trial, neoadjuvant ipilimumab plus nivolumab was compared with adjuvant ipilimumab plus nivolumab, while the subsequent OpACIN-neo trial evaluated 3 different dosing schedules of neoadjuvant ipilimumab plus nivolumab.

As the OpACIN study looked at a very small patient population, the OpACIN-neo study was conducted, says Blank.

READ THE ORIGINAL FULL ARTICLE

The post Dr. Blank on the OpACIN, OpACIN-neo Trials in Stage III Macroscopic Melanoma appeared first on Melanoma Research Victoria.

]]>
Dr. Blank on Predictive Biomarkers in Macroscopic Stage III Melanoma https://melanomaresearchvic.com.au/dr-blank-on-predictive-biomarkers-in-macroscopic-stage-iii-melanoma Mon, 07 Sep 2020 05:41:30 +0000 https://melanomaresearchvic.com.au/?p=15553 Christian U. Blank, MD, PhD, a medical oncologist in the Division of Immunology at the Netherlands Cancer Institute, discusses the future of baseline biomarkers in macroscopic stage 3 melanoma.

The post Dr. Blank on Predictive Biomarkers in Macroscopic Stage III Melanoma appeared first on Melanoma Research Victoria.

]]>
Source: OncLive, August 2020

Christian U. Blank, MD, PhD, a medical oncologist in the Division of Immunology at the Netherlands Cancer Institute, discusses the future of baseline biomarkers in macroscopic stage 3 melanoma.

In the OpACIN trial, investigators compared neoadjuvant ipilimumab (Yervoy) plus nivolumab (Opdivo) with adjuvant ipilimumab plus nivolumab, while the subsequent OpACIN-neo trial evaluated 3 different dosing schedules of neoadjuvant ipilimumab plus nivolumab only. Updated data from the trials were recently presented during the AACR Virtual Meeting II.

For translational analyses from the trial, baseline biomarkers, such as tumor mutational burden (TMB) and interferon gamma expression, were used to predict which patients would have favorable responses to treatment, says Blank.

READ THE ORIGINAL FULL ARTICLE

The post Dr. Blank on Predictive Biomarkers in Macroscopic Stage III Melanoma appeared first on Melanoma Research Victoria.

]]>
Recent Advances in Melanoma https://melanomaresearchvic.com.au/recent-advances-in-melanoma Thu, 03 Sep 2020 07:33:22 +0000 https://melanomaresearchvic.com.au/?p=15536 Grace Cherry, RN, ?MSN, NP, Melanoma Program, University of California, Los Angeles, Jonsson Comprehensive Cancer Center, discusses ?recent advances in melanoma.

The post Recent Advances in Melanoma appeared first on Melanoma Research Victoria.

]]>
Source: OncLive, August 2020

Grace Cherry, RN, MSN, NP, Melanoma Program, University of California, Los Angeles, Jonsson Comprehensive Cancer Center, discusses recent advances in melanoma.

Significant progress has been made in the treatment landscape of melanoma, says Cherry. Moreover, ongoing research suggests that certain combination therapies can re-induce an immune response in patients who progress on PD-1 inhibitors.

Moreover, on July 30, 2020, the FDA approved atezolizumab (Tecentriq) in combination with cobimetinib (Cotellic) and vemurafenib (Zelboraf) for patients with BRAF V600-mutation positive advanced melanoma based on findings from the phase 3 IMspire150 trial.

READ THE ORIGINAL FULL ARTICLE

 

The post Recent Advances in Melanoma appeared first on Melanoma Research Victoria.

]]>
Dr. Weber on Emerging Therapies in Melanoma https://melanomaresearchvic.com.au/dr-weber-on-emerging-therapies-in-melanoma Thu, 27 Aug 2020 07:48:15 +0000 https://melanomaresearchvic.com.au/?p=15500 Jeffrey S. Weber, MD, PhD, deputy director of NYU Langone Health’s Perlmutter Cancer Center; Laura and Isaac Perlmutter Professor of Oncology in the Department of Medicine at NYU Grossman School of Medicine; and the 2016 Giant of Cancer Care® in Melanoma, discusses emerging therapies in melanoma.

The post Dr. Weber on Emerging Therapies in Melanoma appeared first on Melanoma Research Victoria.

]]>
Source: OncLive, August 2020

Jeffrey S. Weber, MD, PhD, deputy director of NYU Langone Health’s Perlmutter Cancer Center; Laura and Isaac Perlmutter Professor of Oncology in the Department of Medicine at NYU Grossman School of Medicine; and the 2016 Giant of Cancer Care® in Melanoma, discusses emerging therapies in melanoma.

In the future, the field can expect to see novel agents used in combination with tumor-infiltrating lymphocyte therapy, as well as novel checkpoints such as sialic acid-binding immunoglobulin-type lectins, says Weber.

Moreover, research evaluating bispecific molecules targeting PD-1, CTLA-4, inducible T-cell costimulator, and OX40 is ongoing, explains Weber.

READ THE ORIGINAL FULL ARTICLE

The post Dr. Weber on Emerging Therapies in Melanoma appeared first on Melanoma Research Victoria.

]]>
Dr. Johnson on the Limitations of Biomarkers in Melanoma https://melanomaresearchvic.com.au/dr-johnson-on-the-limitations-of-biomarkers-in-melanoma Wed, 26 Aug 2020 08:09:31 +0000 https://melanomaresearchvic.com.au/?p=15494 Douglas B. Johnson, MD, MSCI, assistant professor of medicine, Vanderbilt University Medical Center, clinical director, Melanoma Research Program, Vanderbilt-Ingram Cancer Center, discusses the limitations of biomarkers in melanoma.

The post Dr. Johnson on the Limitations of Biomarkers in Melanoma appeared first on Melanoma Research Victoria.

]]>
Source: OncLive, August 2020

Douglas B. Johnson, MD, MSCI, assistant professor of medicine, Vanderbilt University Medical Center, clinical director, Melanoma Research Program, Vanderbilt-Ingram Cancer Center, discusses the limitations of biomarkers in melanoma.

Identifying novel biomarkers in melanoma has been a challenging area of research, says Johnson.

Initially, PD-L1 expression was evaluated as a way to determine whether patients should receive single-agent PD-1 inhibitors or the combination of PD-1 plus CTLA-4 inhibitors, Johnson explains.

READ THE ORIGINAL FULL ARTICLE

The post Dr. Johnson on the Limitations of Biomarkers in Melanoma appeared first on Melanoma Research Victoria.

]]>
Dr. Chandra on the Incidence of Targetable Mutations in Melanoma https://melanomaresearchvic.com.au/dr-chandra-on-the-incidence-of-targetable-mutations-in-melanoma Mon, 10 Aug 2020 13:44:07 +0000 https://melanomaresearchvic.com.au/?p=15466 Sunandana Chandra, MD, MS, assistant professor of medicine, Division of Hematology and Oncology, Northwestern University Feinberg School of Medicine, discusses the incidence of targetable mutations in melanoma.

The post Dr. Chandra on the Incidence of Targetable Mutations in Melanoma appeared first on Melanoma Research Victoria.

]]>
Source: OncLive, July 2020

Sunandana Chandra, MD, MS, assistant professor of medicine, Division of Hematology and Oncology, Northwestern University Feinberg School of Medicine, discusses the incidence of targetable mutations in melanoma.

The MAP kinase pathway is constitutively active in patients with melanoma, particularly for those with BRAF mutations, says Chandra. Moreover, inhibition of this pathway has shown improved outcomes for patients.

BRAF mutations occur in about half of all patients with melanoma, 90% of which are BRAF V600E mutations, explains Chandra. Other potentially actionable genomic mutations include NRAS and KIT, which are each present in around 20% of patients with melanoma. Notably, KIT alterations are often observed in mucosal melanoma and acral melanoma.

READ THE ORIGINAL FULL ARTICLE

The post Dr. Chandra on the Incidence of Targetable Mutations in Melanoma appeared first on Melanoma Research Victoria.

]]>
Dr. Shapiro on the Utility of Complete Lymph Node Dissection in Melanoma https://melanomaresearchvic.com.au/dr-shapiro-on-the-utility-of-complete-lymph-node-dissection-in-melanoma Fri, 07 Aug 2020 02:26:25 +0000 https://melanomaresearchvic.com.au/?p=15457 David R. Gandara, MD, director, Thoracic Oncology Program, professor, senior advisor to director, University of California Davis Comprehensive Cancer Center, and a 2017 Giant of Cancer Care® in Lung Cancer, discusses measuring tumor mutational burden (TMB) in patients with non–small cell lung cancer (NSCLC) who received prior immunotherapy.

The post Dr. Shapiro on the Utility of Complete Lymph Node Dissection in Melanoma appeared first on Melanoma Research Victoria.

]]>
Source: OncLive, July 2020

David R. Gandara, MD, director, Thoracic Oncology Program, professor, senior advisor to director, University of California Davis Comprehensive Cancer Center, and a 2017 Giant of Cancer Care® in Lung Cancer, discusses measuring tumor mutational burden (TMB) in patients with non–small cell lung cancer (NSCLC) who received prior immunotherapy.

Through a host of research tests and comprehensive genomic profiling, TMB can be measured in many ways to determine a patient’s response to immunotherapy, says Gandara.

Three examples include the FoundationOne CDx test in tissue, as well as the Guardant OMNI and FoundationOne Liquid tests in blood. The blood tests, though not commercially available, are currently under development, Gandara concludes.

READ THE ORIGINAL FULL ARTICLE

 

The post Dr. Shapiro on the Utility of Complete Lymph Node Dissection in Melanoma appeared first on Melanoma Research Victoria.

]]>
Dr. Chandra on Unanswered Questions With Targeted Therapy in Melanoma https://melanomaresearchvic.com.au/dr-chandra-on-unanswered-questions-with-targeted-therapy-in-melanoma Thu, 06 Aug 2020 07:38:36 +0000 https://melanomaresearchvic.com.au/?p=15448 Sunandana Chandra, MD, MS, assistant professor of medicine, Division of Hematology and Oncology, Northwestern University Feinberg School of Medicine, discusses unanswered questions regarding the utility of targeted therapy in melanoma.

The post Dr. Chandra on Unanswered Questions With Targeted Therapy in Melanoma appeared first on Melanoma Research Victoria.

]]>
Source: OncLive, July 2020

Sunandana Chandra, MD, MS, assistant professor of medicine, Division of Hematology and Oncology, Northwestern University Feinberg School of Medicine, discusses unanswered questions regarding the utility of targeted therapy in melanoma.

Developing a greater understanding of when to implement targeted therapies, at what point in treatment, and for which patients is critically important in the melanoma space, explains Chandra.

Currently, targeted therapy is used for patients who have a high tumor mutational burden, elevated lactate dehydrogenase, or symptomatic disease, Chandra says. However, there are likely other instances in which targeted therapy would be beneficial for patients.

READ THE ORIGINAL FULL ARTICLE

The post Dr. Chandra on Unanswered Questions With Targeted Therapy in Melanoma appeared first on Melanoma Research Victoria.

]]>
Dr. Glitza Olivia on the Prognosis of Melanoma Brain Metastases https://melanomaresearchvic.com.au/dr-glitza-olivia-on-the-prognosis-of-melanoma-brain-metastases Tue, 04 Aug 2020 08:00:07 +0000 https://melanomaresearchvic.com.au/?p=15434 Isabella C. Glitza Oliva, MD, PhD, MS, an assistant professor within the Department of Melanoma Medical Oncology, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, discusses the prognosis of patients with melanoma brain and/or central nervous system (CNS) metastases.

The post Dr. Glitza Olivia on the Prognosis of Melanoma Brain Metastases appeared first on Melanoma Research Victoria.

]]>
Source: OncLive, July 2020

 

Isabella C. Glitza Oliva, MD, PhD, MS, an assistant professor within the Department of Melanoma Medical Oncology, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, discusses the prognosis of patients with melanoma brain and/or central nervous system (CNS) metastases.

Brain metastases or CNS metastases in melanoma have been a huge issue for many years. Of all the solid tumors, such as breast cancer, lung cancer, and colon cancer, melanoma has the highest likelihood of metastasizing or spreading to the CNS, including the brain and leptomeninges, says Glitza Olivia. Over the past 3 years, fantastic breakthroughs have been made in the treatment of patients with brain metastases, adds Glitza Olivia. However, patients whose disease spreads to the lining of the brain or spinal canal have a very poor prognosis and no therapies have been effective.

READ THE ORIGINAL FULL ARTICLE

The post Dr. Glitza Olivia on the Prognosis of Melanoma Brain Metastases appeared first on Melanoma Research Victoria.

]]>